Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 September 2019 | Story Rulanzen Martin | Photo Sonia Small (Kaleidoscope Studios)
#UFSRun4MentalHealth
The #UFSRun4MentalHealth is an initiative to create awareness around mental health.

Bringing hope to the millions of South Africans suffering from mental illness, is the message the #UFSRun4MentalHealth team wants to resonate when they take on the 1 075 km distance between Bloemfontein and Stellenbosch.  

On Friday 20 September 2019, three teams of enthusiastic runners from the Faculty of Health Sciences and Organisational Development and Employee Wellness at the University of the Free State (UFS) will embark on the first UFS mental-health awareness run to Stellenbosch. Each runner will complete 9 km each day. “We will be passing on the baton of hope. There is hope, and no one is alone,” says Burneline Kaars, Head of Employee Wellness at the UFS. 

The #UFSRun4MentalHealth run will end on the campus of Stellenbosch University (SU) on 25 September 2019, with the symbolic handover of the baton of hope to a representative of the SU management. 

Team Blue

Team Blue. From the left: Jo-mari Horn, Patrick Kaars, Burneline Kaars, Riaan Bezuidenhout, George Dumisi, and Eugene Petrus.
(absent: Hendrik Blom)

#UFSRun4MentalHealth part of larger project

“This initiative is our effort to mitigate the impact of inactivity experienced by our students and staff on their productivity and mental health. The purpose is to raise awareness and motivate people to get active,” says Burneline. Through this effort, the UFS is demonstrating care for student and staff well-being. 

“Well-being is not only the responsibility of the organisation or university, but the responsibility of all of us,” says Prof Francis Petersen, Rector and Vice-Chancellor. “This initiative also demonstrates care – to look after one another, to take care of one another –from the organisation to our people, but also among ourselves.” 

Prof Petersen points out that the #UFSRun4MentalHealth forms part of a larger UFS project called ‘Project Caring’. He is also hopeful that the team’s effort to change the perception of mental health will encourage discussion and openness in the towns they will visit on their way to Stellenbosch.

Team Red. From the left: Arina Meyer, Nico Piedt, Brenda Coetzee, Justin Coetzee, Elna de Waal, De Wet Dimo, and Tertia de Bruin.

Team Red. From the left: Arina Meyer, Nico Piedt, Brenda Coetzee, Justin Coetzee, Elna de Waal, De Wet Dimo, and Tertia
de Bruin.

Putting care into action

“With this run to Stellenbosch, we are putting care into action,” says Susan van Jaarsveld, Senior Director, Human Resources. 
According to the South African Depression and Anxiety Group, 16% or about 9 million of South Africa’s adult population suffer from a mental disorder. “With this increased awareness, we hope that people will share their mental-health diagnoses and that this campaign will help to reduce the stigma surrounding mental health.”  

The #UFSRun4MentalHealth also links to the mission of the UFS Department of Human Resources to create an environment not only for high performance, but for optimal performance.

The sponsors of this initiative are BestMed, Standard Bank, Shell, Annique Health and Beauty, Xerox, Bidvest Car Rental, Media24, Kloppers, New Balance, Clover, Futurelife, Mylan, Pharma Dynamics, and the SA Society of Psychiatrists

Team White. From the left: Thys Pretorius, Lynette van der Merwe, Leon Engelbrecht, Arina Engelbrecht, Teboho Rampheteng, Belinda Putter, and Lucas Swart.

Team White. From the left: Thys Pretorius, Lynette van der Merwe, Leon Engelbrecht, Arina Engelbrecht, Teboho Rampheteng,
Belinda Putter, and Lucas Swart.

 


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept